Developed using technology from partner Seattle Genetics, the drug is a monoclonal antibody containing a toxic chemotherapy that attacks cancer cells if they express glycoprotein NMB, or GPNMB.
Researchers now believe that up to 85% of heart attacks occur when arterial plaques suddenly rupture, spilling toxic substances and triggering a massive clot.